$AMRZ

Gibson Dwight Audley Konrad purchased $244 of AMRZ

Gibson Dwight Audley Konrad purchased 5 shares of Amrize Ltd (AMRZ) at $44.58 on 2026-08-27.

Original reporting
SEC EDGAR · Gibson Dwight Audley Konrad
Published Aug 31, 2026, 7:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 7:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMRZ
Neutral
low confidence
Mentioned
$AMRZ
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZNeutralLow
01

Why it matters

The director's purchase is modest and unlikely to move the stock, but it confirms continued insider ownership.

02

Market read

Limited relevance; only of interest to insiders and very short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions not disclosed yet.

Relevance 4/10Novelty 3/10Timing: after-hours filing on Aug 31

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$AMRZNeutralLow confidence
Context

Director Gibson Dwight Audley Konrad purchased 5 shares for $44.58 each, increasing his stake to 5,199 shares.

Expected impact

No material price movement expected.

Evidence & confidence

The $244 purchase is too small to affect market perception or liquidity.

Market effects

None; the transaction is company‑specific.

None; no broader regional effect.

None

Counterpoint

Even small insider buys can precede larger moves; monitor for follow‑on purchases.

Key entities

  • Amrize Ltd

    Issuer of the securities.

  • Gibson Dwight Audley Konrad

    Director of Amrize Ltd.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Amrize Reports Third Quarter 2026 Results

Amrize Ltd (AMRZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Amrize Reports Third Quarter 2026 Results • Revenues up 2.2% to $3,771 million • Net Income grew 3.3% to $558 million • Adjusted EBITDA increased 0.2% to $1,076 million • Margin expansion of 30 basis points in Building Materials • Completed Rapid Redi-Mix acquisition in Dallas-Fo